阅读说明：本技术 一种可促进胫骨骨密度增加及股骨长度增长的配方奶粉 (Formula milk powder capable of promoting increase of tibial bone density and increase of femoral length ) 是由 李钟� 蒋希 于 2021-08-06 设计创作，主要内容包括：本发明提供一种可促进胫骨骨密度增加及股骨长度增长的配方奶粉,含水解蛋黄粉,初乳碱性蛋白,磷脂酰丝氨酸,N-乙酰神经氨酸,动物双歧杆菌Bb-12、植物乳杆菌GMNL-662等成分,其中水解蛋黄粉含有促进骨骼成长的成,初乳碱性蛋白CBP可直接作用于骨骼细胞,促进骨骼新陈代谢；能协调成骨细胞和破骨细胞的活动,保持两者的动态平衡,促进骨骼生长,修复骨质；植物乳杆菌GMNL-662为专利菌株,可促进骨质再生。本发明通过基础配方奶粉与儿童成长奶粉分别喂养大鼠的实验,测量大鼠胫骨、股骨的长度变化,骨密度(BMD)、I型前胶原氨基端肽(PICT)、骨碱性磷酸酶(BAP)、骨钙素(BGP)等血清生化指标等指标,从而证明本发明配方奶粉具有促进儿童增高的效能。(The invention provides a formula milk powder capable of promoting tibial bone density increase and femoral length increase, which contains hydrolyzed yolk powder, colostrum basic protein, phosphatidylserine, N-acetylneuraminic acid, bifidobacterium animalis Bb-12, lactobacillus plantarum GMNL-662 and other components, wherein the hydrolyzed yolk powder contains ingredients capable of promoting bone growth, and colostrum basic protein CBP can directly act on bone cells to promote bone metabolism; can coordinate the activities of osteoblast and osteoclast, maintain the dynamic balance of the osteoblast and the osteoclast, promote the growth of bones and repair bones; lactobacillus plantarum GMNL-662 is a patent strain and can promote bone regeneration. The invention measures the length change of tibia and femur of a rat, the indexes of serum biochemical indexes such as bone density (BMD), type I procollagen amino-terminal Peptide (PICT), Bone Alkaline Phosphatase (BAP), osteocalcin (BGP) and the like through the experiment that a basic formula milk powder and a child growth milk powder are respectively fed to the rat, thereby proving that the formula milk powder has the efficacy of promoting the height increase of children.)

1. The formula milk powder capable of promoting tibial bone density increase and femoral length increase is characterized by being prepared from 512 parts of whole milk powder, 90384 parts of desalted whey powder, 25 parts of lactose, 56 parts of isomaltooligosaccharide (IMO-50 type), 1 part of fructo-oligosaccharide (95S), 1 part of galacto-oligosaccharide (57S), 3 parts of vitamin pack, 2 parts of mineral pack, 0.5 part of oat whole wheat powder, 0.5 part of Phosphatidylserine (PS), 3 parts of milk mineral salt, 11 parts of calcium carbonate, 0.5 part of hydrolyzed yolk powder, 0.3 part of N-acetylneuraminic acid (cubilose acid), 0.5 part of colostrum basic protein, 1.5 parts of lactobacillus plantarum 662 (100B), 0.5 part of yeast beta-glucan and 0.5 part of vitamin K₂ 0.045 parts of the components.

2. The formula of milk powder according to claim 1, wherein the vitamin bag comprises vitamin A0.01 parts, vitamin D0.01 parts, vitamin E0.02 parts, vitamin K0.03 parts, vitamin B10.04 parts, vitamin B20.03 parts, vitamin B60.01 parts, vitamin B120.02 parts, vitamin C0.032 parts, nicotinic acid 0.012 parts, folic acid 0.01 parts, pantothenic acid 0.021 parts, biotin D0.023 parts, inositol 0.022 parts, and taurine 0.035 parts.

3. The formula of claim 1, wherein the mineral bag comprises calcium carbonate 0.025 parts, ferric pyrophosphate 0.033 parts, zinc oxide 0.0389 parts, sodium selenite 0.028 parts, copper sulfate 0.036 parts, and manganese sulfate 0.041 parts.

Technical Field

The invention belongs to the technical field of milk powder, and particularly relates to formula milk powder capable of promoting increase of tibial bone density and femoral length.

Background

The milk powder is prepared from fresh milk or goat milk by freezing or heating to remove almost all water in milk, drying, and adding appropriate amount of vitamins and minerals. The main nutritional components of the milk powder comprise protein, fat, sugar and the like, and the milk powder has high nutritional value and is suitable for nutritional supplement of people at different ages. The growth and development of children are rapid, the growth of height and weight, the development of intelligence and vision, the continuous improvement of digestive system and immune system and the like, and all need nutrition as material support. The common milk powder is suitable for most people, the children milk powder is specially developed according to the physiological characteristics and nutritional requirements of children, the requirements of the children on basic nutrition and functional nutrition can be met, the nutrition is more comprehensive and more targeted, and the very important nutritional supplement food in the dietary structure of the children plays an important role in promoting the growth and development of the children and improving the immunity.

At present, many brands of children's milk powder exist in the market, most of the children's formula milk powder mainly supplements protein, vitamins, minerals and DHA, but the functional nutrition is not comprehensive enough. Therefore, the formula milk powder capable of promoting the increase of the bone density of the tibia and the increase of the length of the femur has great significance.

Disclosure of Invention

In order to solve the existing problems, the invention provides a formula milk powder capable of promoting the increase of the bone density of the tibia and the increase of the length of the femur, and the specific formula is as follows: the formula milk powder capable of promoting tibial bone density increase and femoral length increase is characterized by being prepared from 512 parts of whole milk powder, 90384 parts of desalted whey powder, 25 parts of lactose, 56 parts of isomaltooligosaccharide (IMO-50 type), 1 part of fructo-oligosaccharide (95S), 1 part of galacto-oligosaccharide (57S), 3 parts of vitamin pack, 2 parts of mineral pack, 0.5 part of oat whole wheat powder, 0.5 part of Phosphatidylserine (PS), 3 parts of milk mineral salt, 11 parts of calcium carbonate, 0.5 part of hydrolyzed yolk powder, 0.3 part of N-acetylneuraminic acid (cubilose acid), 0.5 part of colostrum basic protein, 1.5 parts of lactobacillus plantarum 662 (100B), 0.5 part of yeast beta-glucan and 0.5 part of vitamin K₂ 0.045 parts of the components.

Further, the vitamin bag comprises 0.01 part of vitamin A, 0.01 part of vitamin D, 0.02 part of vitamin E, 0.03 part of vitamin K, 10.04 parts of vitamin B, 20.03 parts of vitamin B, 60.01 parts of vitamin B, 120.02 parts of vitamin B, 0.032 part of vitamin C, 0.012 part of nicotinic acid, 0.01 part of folic acid, 0.021 part of pantothenic acid, 0.023 part of biotin D, 0.022 part of inositol and 0.035 part of taurine. Further, the mineral bag comprises 0.025 parts of calcium carbonate, 0.033 parts of ferric pyrophosphate, 0.0389 parts of zinc oxide, 0.028 parts of sodium selenite, 0.036 parts of copper sulfate and 0.041 parts of manganese sulfate.

Detailed Description

A formula milk powder capable of promoting tibial bone density increase and femoral length increase is prepared from 512 parts of whole milk powder, 90384 parts of desalted whey powder, 25 parts of lactose, 56 parts of isomaltooligosaccharide (IMO-50 type), 1 part of fructo-oligosaccharide (95S), 1 part of galacto-oligosaccharide (57S), 3 parts of vitamin bag, 2 parts of mineral bag, 0.5 part of oat whole wheat powder, 0.5 part of Phosphatidylserine (PS), 3 parts of milk mineral salt, 11 parts of calcium carbonate, 0.5 part of hydrolyzed yolk powder, 0.3 part of N-acetylneuraminic acid (cubilose), 0.5 part of colostrum basic protein, 1.5 parts of lactobacillus plantarum 662 (100B), 0.5 part of yeast beta-glucan and vitamin K₂ 0.045 parts of the components.

The vitamin bag comprises 0.01 part of vitamin A, 0.01 part of vitamin D, 0.02 part of vitamin E, 0.03 part of vitamin K, 10.04 parts of vitamin B, 20.03 parts of vitamin B, 60.01 parts of vitamin B, 120.02 parts of vitamin B, 0.032 part of vitamin C, 0.012 part of nicotinic acid, 0.01 part of folic acid, 0.021 part of pantothenic acid, 0.023 part of biotin D, 0.022 part of inositol and 0.035 part of taurine. The mineral bag comprises 0.025 parts of calcium carbonate, 0.033 parts of ferric pyrophosphate, 0.0389 parts of zinc oxide, 0.028 parts of sodium selenite, 0.036 parts of copper sulfate and 0.041 parts of manganese sulfate.

The length and height test is as follows: 1. material

1.1 sample: the basic formula milk powder and the child growth milk powder are provided by Niujingle (Guangzhou) nutriment Co., Ltd, and are milk white powder for experiments.

1.2 animals: SPF grade healthy male SD rats (14 days old), average body weight 29.39, provided by changsha tianqin biotechnology limited, production license number SCXK (xiang) 2019-: 4307262011001866.

1.3 Experimental conditions: the experimental animals are bred in an SPF (specific pathogen free) animal laboratory of Xiangya public health institute of China and south university at the temperature of 21-23 ℃ and the relative humidity of 50-60%.

1.4 Primary reagents and instruments

Rat Bone Alkaline Phosphatase (BAP) enzyme-linked immunosorbent assay kit, rat type I procollagen amino terminal Peptide (PICT) enzyme-linked immunosorbent assay kit, rat osteocalcin (BGP) enzyme-linked immunosorbent assay kit, rat 25 hydroxy vitamin D (25-OH-VD) enzyme-linked immunosorbent assay kit, CS-T300 type full-automatic biochemical analyzer (Changdui industry Co., Ltd.), H1650R type desk-top high-speed refrigerated centrifuge (Hunan instrument Power test Instrument Co., Ltd.), MB-530 type multifunctional enzyme-linked immunosorbent assay (Shenzhen, Hui Pinke technology development Co., Ltd., LC-20A type liquid chromatograph (Shimadzu).

2. Method of producing a composite material

2.1 Experimental groups

SD rats of 14 days old are randomly divided into 3 groups, namely a basic formula milk powder group (blank group), a low-dose group (1.2 g/d) of the growing-up milk powder of the invention for children, and a high-dose group (3.6g/d) of the growing-up milk powder of the invention, wherein each group contains 12 animals. During the experiment, all groups of animals are quantitatively fed with milk and feed according to the nutrition requirement standard of rats and mice, and the animals are freely drunk at the later stage for 4 weeks.

2.2 detection indices and methods

2.2.1 bone alkaline phosphatase, type I procollagen amino-telopeptide, osteocalcin, 25-hydroxyvitamin D

Bone alkaline phosphatase, type I procollagen amino terminal peptide, osteocalcin and 25 hydroxy vitamin are respectively measured by a rat alkaline phosphatase (BAP) enzyme-linked immunosorbent assay kit, a rat type I procollagen amino terminal Peptide (PICT) enzyme-linked immunosorbent assay kit, a rat osteocalcin (BGP) enzyme-linked immunosorbent assay kit and a rat 25 hydroxy vitamin (25-OH-VD) enzyme-linked immunosorbent assay kit.

2.2.2 bone Length and bone Density

Measuring the length of the femur and tibia of the rat by using a vernier caliper; bone density of rat femur and tibia was measured using a dual-energy X-ray bone densitometer.

2.3 statistical methods

Measuring data by meanThe standard deviation indicates that the data processing is performed using the SPSS18.00 software package. If the data is normally distributed and the variance among the groups is uniform, adopting single-factor variance analysis to obtainPDifferences of less than or equal to 0.05 are statistically significant.

3. Results

3.1 the Effect of the milk powder of the invention on the serum biochemical indexes of rats

3.1.1 Effect of the invention on serum 25 hydroxy vitamin D in rats

Measuring the content of 25 hydroxyvitamin D in serum of rats when the rats are fed for 14 days, and statistically analyzing the content of 25 hydroxyvitamin D in serum among groups by formula difference analysis (P= 0.015). The serum 25-hydroxyvitamin D content was statistically different between the high dose group and the base powder group as analyzed by pairwise comparisons (table 1).

TABLE 1 Effect of the present invention on serum 25 hydroxyvitamin D in rats

Measuring the content of 25 hydroxyvitamin D in serum of rats when the rats are fed for 28 days, and statistically analyzing the content of 25 hydroxyvitamin D in serum among groups by formula difference analysis (P= 0.008). The serum 25-hydroxyvitamin D content was statistically different between the high dose group and the base powder group as analyzed by pairwise comparisons (table 2).

TABLE 2 Effect of the present invention on serum 25 hydroxyvitamin D in rats

3.1.2 Effect of the child milk powder of the invention on rat serum osteocalcin

Measuring the serum osteocalcin content of rats when the rats are fed for 14 days, and analyzing by prescription difference, wherein the serum osteocalcin content between groups has no statistical difference (P= 0.865). (Table 3).

TABLE 3 Effect of the present invention on mouse serum osteocalcin

Measuring the serum osteocalcin content of rats when the rats are fed for 28 days, and statistically differentiating the serum osteocalcin content among the groups by analysis of formula (P= 0.001). The serum osteocalcin content between the high dose group and the low dose group, between the high dose group and the base powder group, and between the low dose group and the base powder group were statistically different, as analyzed by pairwise comparison (table 4).

TABLE 4 Effect of the present invention on rat serum osteocalcin

3.1.3 Effect of the Children of the invention on serum bone alkaline phosphatase in rats

The serum bone alkaline phosphatase content of the rats was measured at 14 days of feeding, and there was no statistical difference in serum bone alkaline phosphatase content between groups by the analysis of formula differences: (P= 0.280). (Table 5).

TABLE 5 Effect of the present invention on serum alkaline phosphatase in rats

Measuring the serum bone alkaline phosphatase content of the rats when the rats are fed for 28 days, and statistically analyzing the serum bone alkaline phosphatase content among the groups (P= 0.003). The levels of serum bone alkaline phosphatase were statistically different between the high dose group and the base powder group and between the low dose group and the base powder group, as analyzed by pairwise comparison (Table 6).

TABLE 6 Effect of the present invention on serum bone alkaline phosphatase in rats

3.1.4 Effect of the Children's milk powder of the present invention on the serum type I procollagen amino-terminal peptide of rat

Measuring the content of the serum type I procollagen amino-terminal peptide of the rats when the rats are fed for 14 days, and statistically analyzing the content of the serum type I procollagen amino-terminal peptide among groups by formula difference analysis (the content of the serum type I procollagen amino-terminal peptide in the groups is different from the group to the group by formula difference analysis)P= 0.006). The content of amino-terminal peptide of serum type I procollagen was statistically different between the high dose group and the base powder group by two-by-two comparative analysis (Table 7).

TABLE 7 Effect of the present invention on the serum type I procollagen aminotelopeptide in rats

Measuring the content of serum type I procollagen amino-terminal peptide in rats fed for 28 days, and statistically analyzing the content of serum type I procollagen amino-terminal peptide in groups by formula difference analysis (P=0.042). The content of amino-terminal peptide of serum type I procollagen was statistically different between the high dose group and the base powder group by two-by-two comparative analysis (Table 8).

TABLE 8 Effect of the present invention on the serum type I procollagen aminotelopeptide in rats

3.2 Effect of the Children's milk powder of the invention on bone mineral Density of rats

3.2.1 Effect of the Children's milk powder of the invention on bone density of femur of rat

Measuring the bone density of the femur of the rats when the rats are fed for 14 days, and the bone density of the femur between the rats has no statistical difference through analysis of prescriptions (1)P= 0.750). (Table 9).

TABLE 9 Effect of the Children's milk powder of the present invention on bone density of femur of rat

Measuring the bone density of the femur of the rat when the rat is fed for 28 days, and having no statistical difference of the bone density of the femur among the groups through analysis of different prescriptions (P= 0.057). (Table 10).

TABLE 10 Effect of the Children's milk powder of the present invention on bone density of femur of mice

3.2.2 Effect of the Children's milk powder of the invention on the tibial bone density of rats

The tibial bone density of the rats is measured at 14 days of feeding, and the tibial bone density between the groups has no statistical difference through analysis of prescriptions and differences (P= 0.789). (Table 11).

TABLE 11 Effect of the Children's milk powder of the present invention on the tibial bone Density of rats

The tibial bone density of the rats is measured when the rats are fed for 28 days, and the tibial bone density between the rats is statistically different by the analysis of the formula difference (P= 0.009). The analysis of pairwise comparisons showed a statistical difference in tibial bone density between the high and low dose groups (table 12).

TABLE 12 Effect of the Children's milk powder of the present invention on the tibial bone Density of rats

3.3 Effect of the Children of the invention on the bone Length of the rats

3.3.1 Effect of the Children of the invention on the femoral Length of rats

Measuring the length of femur of rats when feeding for 14 days, and analyzing by the difference of prescriptions, the length of femur between groups has no statistical difference: (P= 0.518). (Table 13).

TABLE 13 Effect of the present invention on femur length in rats

Measuring the length of femur of rats when the rats are fed for 28 days, and statistically differentiating the length of femur among the groups by analysis of the difference of prescriptions (P<0.001). The analysis of the pairwise comparisons showed statistical differences in femoral length between the high and low dose groups, the high and base powder groups (table 14).

TABLE 14 Effect of the present invention on femur length in rats

3.3.2 Effect of the Children's milk powder of the invention on the tibial length of rats

The length of the tibia of the rats was measured at 14 days of feeding, and there was no statistical difference in the length of the tibia between the groups by the analysis of the equation: (P= 0.702). (Table 15).

TABLE 15 Effect of the present invention on tibial length of rats

Measuring the length of tibia of rats when feeding for 28 days, and analyzing by the difference of prescriptions, wherein the length of tibia between groups has no statistical difference: (P= 0.081). (Table 16).

TABLE 16 Effect of the present invention on tibial length of rats

4. Conclusion

According to the experimental results, under the experimental conditions, the children growth milk powder can improve the contents of 25-hydroxy vitamin D, osteocalcin, bone alkaline phosphatase and I-type procollagen amino-terminal peptide in rat serum, and can promote the increase of the bone density of the tibia and the length of the femur of the rat.